Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
Date:5/13/2009

1,411 3,604 TOTAL OPERATING EXPENSES 2,986 33,451 OPERATING INCOME (LOSS) 344 (33,252) OTHER INCOME (EXPENSE): Interest and other income (expense), net 107 (1,203) INCOME (LOSS) FROM CONTINUING OPERATIONS 451 (34,455) Loss from discontinued operations -- (81) NET INCOME (LOSS) $ 451 $(34,536) NET INCOME (LOSS) PER COMMON SHARE Continuing operations $ 0.01 $ (0.79) Discontinued operations -- (--)* Basic and diluted net income (loss) per common share $ 0.01 $ (0.79) SHARES USED IN COMPUTING NET (INCOME) LOSS PER COMMON SHARE Basic 47,853,895 43,718,077 Diluted 48,050,220 43,718,077 * Amount less than one cent.

    Balance Sheet Information:

                                           March 31, 2009   December 31, 2008*
                                               (unaudited)
    Cash, cash equivalents, interest
     receivable and short-term investment
     securities                                  $15,446             $15,467
    Long-term investment securities                7,117               7,185
    Total assets                                  26,445              26,634
    Accumulated deficit                         (331,467)           (331,918)
    Stockholders' deficit                           (467)             (1,489)

    * Condensed from audited financial statements.


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
5. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
7. Keryx Biopharmaceuticals Receives Nasdaq Notification
8. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
9. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
10. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
11. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Thousands of DePuy Pinnacle hip lawsuits ... who were allegedly injured by a metal-on-metal version of ... in U.S. District Court, Northern District of Texas, Bernstein ... July 18, 2014, U.S. District Judge Ed Kinkeade has ... Steering Committee that sought the deposition of a witness ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, ... at risk of contracting meningitis because of specific health ... updated recommendations from the largest pediatrician group in the ... potentially deadly infection should continue for adolescents and college ... its first statement on meningococcal vaccines since 2011, the ...
(Date:7/28/2014)... do not divide unless there is enough oxygen present ... other cell types circumvent this rule. Researchers at The ... overrides the cells, warning signals, enabling cancers to continue ... the process, the researchers found that lysosomes the ... decisions. They also uncovered new evidence that certain drugs ...
(Date:7/28/2014)... you,ve ordered at a restaurantor when something captures ... brain. , These waves are called gamma ... excitatory and inhibitoryplaying together in an orchestrated way. ... have been associated with higher-level brain function, and ... schizophrenia, Alzheimer,s disease, autism, epilepsy and other disorders. ...
(Date:7/28/2014)... 28, 2014 Mirena IUD lawsuits ( ... caused some users to suffer serious injuries after it ... continue to mount in U.S. courts, Bernstein Liebhard LLP ... last month in New Jersey, at least 924 Mirena ... litigation underway in Bergen County Superior Court. Some 148 ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 2Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 3Health News:Cell's recycling center implicated in division decisions 2Health News:Memory relies on astrocytes, the brain's lesser known cells 2Health News:Memory relies on astrocytes, the brain's lesser known cells 3Health News:Mirena IUD Lawsuit Filings Exceed 920 in New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena IUD Lawsuit Filings Exceed 920 in New Jersey Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena IUD Lawsuit Filings Exceed 920 in New Jersey Litigation, Bernstein Liebhard LLP Reports 4
... -- Chindex International,(Nasdaq: CHDX ) today announced ... for the Ernst & Young Entrepreneur Of The ... to Ernst & Young LLP, the awards,program recognizes ... innovation, financial performance and personal commitment to,their businesses ...
... Atlas Spine, Inc., a spinal,technology development company ... today the national launch of the STATURE Vertebral ... MIS compatible spacer,system designed to utilize a self-distracting ... thoracic and lumbar spine., "After significant developmental ...
... new, highly-advanced walking robot: Flame. This type of research, for ... is important as it provides insight into how people walk. ... improved diagnoses, training and rehabilitation equipment. , If you try ... how complex an activity it is. Walking robots have been ...
... Ontario implements a ban on the retail display of ... Research Unit at the University of Toronto shows that ... point of sale. , Places where tobacco is sold ... communicate with current, former and potential smokers through large ...
... GENERATION OF SCIENTISTS, ELIZABETH, N.J., May 22 ... announced today the,establishment of the Alliance/Merck Ciencia Scholars ... higher education and,degrees in science, technology, engineering and ... $4 million grant from The Merck Company Foundation,the ...
... pioneering research with counselors June 6; provides CEUs, ... to a Ph.D. with the,last name of "Trotter," ... a horse can be more beneficial than traditional ... with other,mental health professionals during her premier Equine ...
Cached Medicine News:Health News:Chindex International, CEO, Roberta Lipson Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Finalist in Greater Washington 2Health News:Chindex International, CEO, Roberta Lipson Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Finalist in Greater Washington 3Health News:Atlas Spine Launches Stature(TM) Vertebral Body Replacement System 2Health News:TU Delft robot Flame walks like a human 2Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 2Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 3Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 4Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 5Health News:Equine Partners in Counseling (EPIC) Training Is Changing the Face of Mental Health 2
(Date:7/28/2014)... (NYSE: RMD ), an innovator and pioneer ... and other chronic respiratory conditions, has won a permanent ... medical device manufacturer APEX Medical Corp. (APEX), prohibiting sales ... 220 masks.  The judgment was entered by the Regional ... appealable, and applies throughout Germany.  The ...
(Date:7/28/2014)... , July 28, 2014  ANI Pharmaceuticals, Inc. (NASDAQ: ... plans to release its second quarter and year-to-date 2014 ... opening of the U.S. financial markets. The earnings press ... of the Company,s website, www.anipharmaceuticals.com . ... Officer, and Charlotte C. Arnold , Vice President ...
(Date:7/28/2014)... , July 28, 2014  ProteinSimple announced today ... the Simple Western. This new assay allows users to detect ... first time, Simple Western users can analyze proteins without ... Simple Western has changed protein analysis as we know ... Western blot protocols - no messy gels, no transfer ...
Breaking Medicine Technology:ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2ANI Pharmaceuticals Schedules Conference Call for Second Quarter 2014 Financial Results 2ProteinSimple Says "Never Run a Gel Again!" 2
... VioQuest,Pharmaceuticals (OTC Bulletin Board: VQPH) today ... of Lenocta(TM) (sodium stibogluconate), a novel,protein tyrosine ... immune stimulant approved for the treatment of ... cancers. The open-label Phase IIa study is,designed ...
... CuraGen Corporation,(Nasdaq: CRGN ), a clinical-stage biopharmaceutical ... Exchange: TOPO) announced,today that updated preliminary clinical trial ... T-cell lymphomas, and new preclinical data,evaluating belinostat on ... 2007 American Society of Hematology (ASH) 49th Annual ...
Cached Medicine Technology:VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor 2VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor 3VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor 4CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 2CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 3CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 4CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 5
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: